Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on August 31, 2021. The report addresses corporate governance matters specifically regarding the scheduling of the company's 2021 Annual Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder meeting logistics and does not contain financial performance data.
Material Changes
The primary material change reported is the rescheduling of the 2021 Annual Meeting of Shareholders. The meeting was originally scheduled for June 30, 2021, and reconvened, but the company was unable to achieve a quorum on either occasion. Consequently, the Board of Directors established a new date for the meeting.
Guidance, Outlook, and Management Commentary
- New Meeting Date: The rescheduled 2021 Annual Meeting will be held on November 22, 2021.
- Regulatory Compliance: Because the new date is more than 30 days from the anniversary of the 2020 Annual Meeting, the company is notifying shareholders in accordance with Rule 14a-5(f) under the Exchange Act.
- Shareholder Proposals: A new deadline for shareholder proposals intended for inclusion in the proxy statement has been set. Proposals must be received by October 1, 2021.
- Submission Details: Proposals and nominations must be delivered to the Corporate Secretary at the company's principal executive offices in Tampa, Florida.
Key Facts for Investor Verification
- Verify the specific record date, time, and location for the November 22, 2021 Annual Meeting once the proxy statement is released.
- Confirm the October 1, 2021 deadline for submitting shareholder proposals under Rule 14a-8.
- Review the upcoming proxy statement for details on director nominations and other agenda items.
- Note that the filing was signed by Michael Sullivan, Interim Principal Executive Officer and Chief Financial Officer.